Wegovy vs Zepbound
Published Jul 4, 2026 · 4 minute read
Wegovy and Zepbound are the two big names in prescription weight management, and unlike Ozempic vs Wegovy, this matchup is between two genuinely different molecules. If you understand this comparison, you understand the whole weight-loss drug rivalry.
Key Takeaways
- Wegovy and Zepbound are both approved for chronic weight management, but they are different molecules.
- Wegovy is semaglutide (a GLP-1 agonist) from Novo Nordisk; Zepbound is tirzepatide (a dual GIP/GLP-1 agonist) from Eli Lilly.
- In separate pivotal trials, the highest Zepbound dose showed larger mean weight loss than the highest Wegovy dose.
- These are different trials, not a head-to-head, so the comparison is indicative and individual results vary.
- Both are once-weekly injections; Wegovy also has an oral pill version.
- This page is educational and is not medical advice.
1. The Short Answer
Both Wegovy and Zepbound are approved for chronic weight management, but they are built on different active ingredients from different companies.
| Wegovy | Zepbound | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Receptors targeted | GLP-1 | GIP + GLP-1 |
| Maker | Novo Nordisk | Eli Lilly |
| Schedule | Once weekly | Once weekly |
| Diabetes counterpart | Ozempic | Mounjaro |
For the molecule deep dive, see Semaglutide vs Tirzepatide.
2. Same Goal, Different Molecule
This is the key mental model. Wegovy and Zepbound share an approved purpose, weight management, but get there with different mechanisms:
- Wegovy (semaglutide): a single GLP-1 receptor agonist.
- Zepbound (tirzepatide): a dual GIP/GLP-1 receptor agonist.
Zepbound also carries an additional approved use for obstructive sleep apnea in certain adults with obesity, while Wegovy carries indications such as cardiovascular-risk reduction and a liver indication.
3. What the Trials Showed
Each brand has a pivotal Phase 3 obesity trial: STEP 1 for Wegovy’s semaglutide, SURMOUNT-1 for Zepbound’s tirzepatide.
4. The Four-Brand Map
Wegovy and Zepbound each have a diabetes-labeled sibling using the same molecule. Seeing all four at once removes most of the confusion.
See also Semaglutide vs Tirzepatide and Ozempic vs Mounjaro for the molecule-level matchups.
5. How to Keep It Straight
- Wegovy = semaglutide, one receptor, Novo Nordisk.
- Zepbound = tirzepatide, two receptors, Eli Lilly.
- Both are weight-management brands; their diabetes twins are Ozempic and Mounjaro.
6. Tracking Either One
For personal records, log the brand, molecule, dose, timing, and injection site consistently. See the Wegovy tracking guide and Zepbound tracking guide.
7. Wegovy vs Zepbound FAQ
Are Wegovy and Zepbound the same thing?
No. Both are approved for chronic weight management, but they contain different molecules. Wegovy is semaglutide from Novo Nordisk, and Zepbound is tirzepatide from Eli Lilly.
Which works better for weight loss, Wegovy or Zepbound?
In separate Phase 3 obesity trials, the highest Zepbound (tirzepatide) dose showed greater mean weight loss (about 20.9%) than the highest Wegovy (semaglutide) dose (about 14.9%). Because these are different trials, the comparison is indicative rather than a direct head-to-head, and individual outcomes vary. This is not medical advice.
What is the mechanism difference between Wegovy and Zepbound?
Wegovy's semaglutide activates one receptor, GLP-1. Zepbound's tirzepatide activates two, GIP and GLP-1. That extra receptor target is the core mechanistic difference.
Do Wegovy and Zepbound have diabetes counterparts?
Yes. The same molecules are sold under diabetes brands: Wegovy's semaglutide is also Ozempic, and Zepbound's tirzepatide is also Mounjaro.
Are both injections, or is there a pill?
Both Wegovy and Zepbound are once-weekly injections. Semaglutide also comes as oral tablets (an oral Wegovy pill and Rybelsus for diabetes); tirzepatide is currently injectable only.